Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

AHT celebrates groundbreaking cancer research
Rupert - the first patient to receive radiotherapy at the centre
Rupert was the first patient to receive radiotherapy at the centre.

Uveal melanoma work could provide a minimally invasive test

Two years after opening the doors to its cancer centre, the Animal Health Trust (AHT) is celebrating its progress so far. It has also revealed the results of some of its groundbreaking research.

Since HRH The Princess Royal opened the AHT's Kennel Club Cancer Centre late in 2012, it has treated over 130 dogs with 15 types of cancer. To date, it has also administered more than 1,300 doses of radiation. With a growing caseload, 2015 is set to be the centre's busiest year yet.

Research undertaken at the centre over the past year could result in a minimally invasive test for uveal melanomas - similar to a test that is already used in humans.

Uveal melanomas are the most common form of primary eye cancer, and are seen in all dog breeds. Currently, the only way to predict whether they will spread is to remove the affected eye or a significant part of the eye. As a result, eyes are sometimes removed unnecessarily as the tumour is found to be benign.

AHT researchers, however, have discovered several "biomarkers" that are present in different quantities in uveal melanomas that have spread, and those that have not. These biomarkers can be measured with just a small number of cells collected from the eye using a fine needle.

This discovery could lead to the development of a minimally invasive test to predict whether uveal melanomas will spread. Patients would therefore not need to undergo anaesthesia and surgery for a tumour biopsy. A fine-needle aspirate-based test is already available for uveal melanomas in humans.

Future research at the centre will use the same methodology to anaylse oral melanomas and mast cell tumours - two of the most common types of cancer seen in dogs. It is hoped this work will lead to the development of better prognostic tests, helping clinicians to choose the most appropriate treatment for affected dogs.

Dr Mark Vaudin, the AHT's CEO, said: "We’re hopeful that in the future we’ll be even closer to developing tests which will help vets to more accurately diagnose and treat cancers in dogs."

The build of the cancer centre was funded by a £1.5 million loan from the Kennel Club, which the AHT repaid in full this week.

As well as treating dogs, the cancer centre also takes on cat and horse cases. It offers a full spectrum of treatments including surgery, chemotherapy and radiotherapy, on the same site as its dog cancer research programme.

Image courtesy of the AHT

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.